BOWEL MALIGNANCY MASQUERADING AS RENAL MASS: A DIAGNOSTIC CHALLENGE

Authors

  • Asif Husain Osmani Department of Oncology, Dr Ziauddin Hospital and Ziauddin University

Keywords:

Renal mass, lower GI pathology, un resect able

Abstract

Metastasis to the kidney in patients without evidence of a widespread nonrenal malignancy is rare since focal renal mass is more likely to represent a primary renal tumour. We present a case of 56-year-old man with renal mass presented with a pain in right lumber region for two months, accompanied by intermittent episodes of Malena. PET CT scan revealed large FDG avid hypo dense mass lesion with markedly increased metabolic activity is identified in the segment VI of the liver, right adrenal gland, upper and mid pole of the right kidney along with abdominal lymph nodes with infiltrating tumour thrombus. Biopsy of mass was consistent with Metastatic Carcinoma Immunohistochemical profile consistent with CK 7, CK 20, villin, CDX2, SA-B2 positive in tumour cells whereas MUC5AC and Hep-Par-1 were negative, favouring lower gastrointestinal tract. He was treated with Fluorouracil and Oxaliplatin based chemotherapy protocol in combination with Bevacizumab with a palliative intent.

References

1. Bracken RB, Chica G, Johnson DE, Luna M. Secondary renal neoplasms: an autopsy study. South Med J 1979;72(7):806–7.

2. Patel U, Ramachandran N, Halls J, Parthipun A, Slide C. Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT. AJR Am J Roentgenol 2011;197(4):W680–6.

3. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int 2016;117(5):775–82.

4. Sánchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, et al. A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer 2004;101(10):2195–201.

5. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009;181(5):2033–6.

6. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study." J Clin Oncol 2023;41(21):3663–9.

7. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. "Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group." Lancet 2015;385(9980):1843–52.

8. Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13(10):2296.

9. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Res 2018;11(4):264–73.

10. Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, et al. Treatment of Patients with Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol 2020;6:414–38.

11. Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, et al. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget 2015;6(39):42334–44.

Published

2026-05-21

How to Cite

1.
Osmani AH. BOWEL MALIGNANCY MASQUERADING AS RENAL MASS: A DIAGNOSTIC CHALLENGE. J Ayub Med Coll Abbottabad [Internet]. 2026 May 21 [cited 2026 May 22];37(4). Available from: https://jamc.ayubmed.edu.pk/index.php/jamc/article/view/13566

Issue

Vol. 37 No. 4 (2025): 37-4

Section

CASE REPORT

License

Copyright (c) 2026 Asif Husain Osmani

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.